PDCD1 and hepatocellular carcinoma: Furthermore, the combination of PD-1 and VEGFR-2 blockade increased PD-1 expression in tumor-infiltrating CD4+ T cells, and those cells were able to promote vasculature normalization in hepatocellular carcinoma models [174].